

Heat and High pH Forced Degradation of Antibodies on a Biozen™ dSEC-2 Column

Tanya Napolitano, PhD, Ivan Lebedev, PhD, and Bryan Tackett, PhD Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA

Overview

The shelf life and storage considerations of various monoclonal antibodies (mAbs) heavily depend on their inherent biophysical properties. Size exclusion chromatography (SEC) provides an opportunity to elucidate the behaviors of proteinatious material with respect to time. Temperature and alkalinity can affect the longevity of an antibody in solution. In this application note, we demonstrate the aggregation propensity of multiple antibodies in response to their environmental conditions using a Biozen dSEC-2 column.

To test high temperature conditions for mAb degradation, we heated two antibodies, Herceptin and Cetuximab, at 60°C while taking aliquots every 24 hours across 168 hours. High temperature stress is one of the most relevant conditions for providing information about potential long-term degradation at the intended storage condition. High temperature was found to accelerate the formation of aggregates (**Figures 1** and **2**) which were successfully separated from the monomer using the Biozen dSEC-2 column.

To evaluate pH, the storage solution was adjusted to pH 9 from the initial storage pH of 6-7. Infliximab and Cetuximab were each incubated under alkaline conditions at 37°C for 72 hours with aliquots sampled at 24-hour intervals. It was observed that the combination of physiological temperature as well as high pH leads to the degradation of the antibodies through cleavage of their disulfide bonds at the hinge and domain interfaces (**Figures 3** and **4**).

This application note demonstrates the applicability of the Biozen dSEC-2 column in understanding the biophysical integrity monoclonal antibodies and related proteins. Stability studies have been shown to generate impurities that feature a degree of denaturization thus exposing some hydrophobic regions of the folded protein's interior. The hydrophilic nature of the Biozen dSEC-2 stationary phase shows favorable aggregate profiles for forced degradation work under high salt conditions which is a known challenge when working with more hydrophobic hybrid particles for these studies.

LC Conditions

Column: Biozen 1.8 µm dSEC-2

Dimension: 300 x 4.6 mm **Part No.:** 00H-4787-E0

Mobile Phase: 200 mM Potassium Phosphate + 250

mM Potassium Chloride, pH 6.2

Flow Rate: 0.35 mL/min
Injection 2 μL (Herceptin)

Volume: 10 μL (Cetuximab, Infliximab)

Temperature: 25 °C

Detector: UV @ 280 nm

System: Waters® ACQUITY® UPLC H-Class

Samples: 1. Herceptin (10 mg/mL)

Cetuximab (2 mg/mL)
 Infliximab (2 mg/mL)

Figure 1. Herceptin Day 0, 3, and 7 Forced Degradation by Heat Analysis on a Biozen™ dSEC-2 Column.




Figure 2. Cetuximab Day 0, 3, and 7 Forced Degradation by Heat Analysis on a Biozen dSEC-2 Column.




Figure 3. Cetuximab Day 0 and 3 Forced Degradation by High pH Analysis on a Biozen™ dSEC-2 Column.





Figure 4. Infliximab Day 0 and 3 Forced Degradation by High pH Analysis on a Biozen dSEC-2 Column.



Need a different column size or sample preparation format?

No problem! We have a majority of our available dimensions up on www.phenomenex.com, but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal www.phenomenex.com/Chat.

t: +61 (0)2-9428-6444 auinfo@phenomenex.com

Austria

t: +43 (0)1-319-1301 anfrage@phenomenex.com

Belaium

t: +32 (0)2 503 4015 (French) t: +32 (0)2 511 8666 (Dutch) beinfo@phenomenex.com

Canada t: +1 (800) 543-3681 info@phenomenex.com

t: +86 400-606-8099 cninfo@phenomenex.com

Czech Republic

t: +420 272 017 077 cz-info@phenomenex.com

Denmark

t: +45 4824 8048 nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063 nordicinfo@phenomenex.com

France t: +33 (0)1 30 09 21 10 franceinfo@phenomenex.com

Germany t: +49 (0)6021-58830-0 anfrage@phenomenex.com

Hong Kong

t: +852 6012 8162 hkinfo@phenomenex.com

India

t: +91 (0)40-3012 2400 indiainfo@phenomenex.com

Indonesia

t: +62 21 5019 9707 indoinfo@phenomenex.com

t: +353 (0)1 247 5405 eireinfo@phenomenex.com

Italy t: +39 051 6327511 italiainfo@phenomenex.com

Japan

t: +81 (0) 120-149-262 jpinfo@phenomenex.com

Luxembourg t: +31 (0)30-2418700 nlinfo@phenomenex.com

Mexico

t: 01-800-844-5226 tecnicomx@phenomenex.com

The Netherlands

t: +31 (0)30-2418700 nlinfo@phenomenex.com

New Zealand

t: +64 (0)9-4780951 nzinfo@phenomenex.com

Norway t: +47 810 02 005 nordicinfo@phenomenex.com

Poland

t: +48 22 104 21 72 pl-info@phenomenex.com

Portugal t: +351 221 450 488 ptinfo@phenomenex.com

Singapore t: +65 6559 4364 sginfo@phenomenex.com

Slovakia t: +420 272 017 077 sk-info@phenomenex.com

t: +34 91-413-8613 espinfo@phenomenex.com

Sweden

t: +46 (0)8 611 6950 nordicinfo@phenomenex.com

Switzerland

t: +41 (0)61 692 20 20 swissinfo@phenomenex.com

Taiwan

t: +886 (0) 0801-49-1246 twinfo@phenomenex.com

Thailand

t: +66 (0) 2 566 0287 thaiinfo@phenomenex.com

United Kingdom

t: +44 (0)1625-501367 ukinfo@phenomenex.com

t: +1 (310) 212-0555 www.phenomenex.com/chat

All other countries/regions Corporate Office USA

t: +1 (310) 212-0555 www.phenomenex.com/chat

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com



Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right.

www.phenomenex.com/behappy

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at www.phenomenex.com/TermsAndConditions.

Trademarks

Biozen and BE-HAPPY are trademarks of Phenomenex. Waters and ACQUITY are registered trademarks of Waters Technologies Corporation. Disclaimer

Comparative separations may not be representative of all applications Phenomenex is in no way affiliated with Waters Technologies Corporation.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2022 Phenomenex, Inc. All rights reserved.